Blossom Bioscience was founded as a joint venture between Cormorant Asset Management and Hansoh Pharmaceuticals.
The relationships with our founders provide broad capabilities and access with Hansoh Pharma providing pre-clinical, clinical and commercialization support to expedite the development and launch of novel assets in Greater China and Cormorant providing support for in-licensing activities by leveraging its extensive global biotech network and portfolio companies.
Hansoh Pharma is a leading biopharmaceutical company in Asia, committed to improving human health through continuous innovation, with more than 10,000 employees in China and the United States. Founded in 1995, Hansoh Pharma is an innovative pharmaceutical company integrating R&D, manufacturing and sales. Hansoh is a leader in oncology, CNS, anti-infectives and diabetes.
Cormorant Asset Management
Cormorant Asset Management, LP is a leading life sciences focused investment firm founded and led by Bihua Chen. Cormorant has focused exclusively on the healthcare industry and invests in companies that discover and develop therapeutic drugs or medical technology throughout their growth cycle. Cormorant is among the most active life-science crossover investors in terms of number of investments since 2015 with investments in over 100 privately held, life science-focused companies over this period.